Pilot Study of Immunogenicity and Tolerability to the Quadrivalent Human Papillomavirus Virus-like Particle (VLP) Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy Compared to Healthy Children and Youth Adult Females.
Phase of Trial: Phase III
Latest Information Update: 26 May 2011
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 26 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2010 New trial record